BR112023005853A2 - Processo para preparar um composto de fórmula i, compostos, processos para preparar o composto 1, forma cristalina, composição farmacêutica, processo de preparação da forma cristalina do composto i e método para tratar uma condição neurodegenerativa - Google Patents
Processo para preparar um composto de fórmula i, compostos, processos para preparar o composto 1, forma cristalina, composição farmacêutica, processo de preparação da forma cristalina do composto i e método para tratar uma condição neurodegenerativaInfo
- Publication number
- BR112023005853A2 BR112023005853A2 BR112023005853A BR112023005853A BR112023005853A2 BR 112023005853 A2 BR112023005853 A2 BR 112023005853A2 BR 112023005853 A BR112023005853 A BR 112023005853A BR 112023005853 A BR112023005853 A BR 112023005853A BR 112023005853 A2 BR112023005853 A2 BR 112023005853A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- compound
- crystalline form
- processes
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 229940125904 compound 1 Drugs 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 239000000376 reactant Substances 0.000 abstract 2
- SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 239000010970 precious metal Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Catalysts (AREA)
Abstract
PROCESSO PARA PREPARAR UM COMPOSTO DE FÓRMULA I, COMPOSTOS, PROCESSOS PARA PREPARAR O COMPOSTO 1, FORMA CRISTALINA, COMPOSIÇÃO FARMACÊUTICA, PROCESSO DE PREPARAÇÃO DA FORMA CRISTALINA DO COMPOSTO I E MÉTODO PARA TRATAR UMA CONDIÇÃO NEURODEGENERATIVA. São fornecidos processos para a preparação de compostos bi-heteroarila, incluindo o composto bi-heteroarila 3-(difluorometóxi)-5-[2-(3,3-difluoropirrolidin-1-il)-6-[(1S,4S)-2-oxa-5- azabiciclo[2.2.1]heptan-5-il]pirimidin-4-il]piridin-2-amina. Entre outras vantagens, os processos proporcionam: o uso de solventes relativamente atóxicos e de baixo custo; uso reduzido de catalisadores de metais preciosos caros; redução da temperatura de reação em determinadas etapas; o uso de agentes de oxidação relativamente não tóxicos; o uso de catalisadores baratos de metais de transição; uma redução das razões molares de certos reactantes, melhorando assim a eficiência do processo enquanto reduz o custo e o desperdício; concentrações de reactante significativamente mais altas em certas etapas; eliminação da necessidade de múltiplas etapas de purificação cromatográfica; eliminação da necessidade de certas etapas de extração usando solvente orgânico; e proporcionar maior rendimento e pureza melhorada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087109P | 2020-10-02 | 2020-10-02 | |
| PCT/US2021/053005 WO2022072721A1 (en) | 2020-10-02 | 2021-09-30 | Process for the preparation of biheteroaryl compounds and crystal forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005853A2 true BR112023005853A2 (pt) | 2023-05-02 |
Family
ID=78599176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005853A BR112023005853A2 (pt) | 2020-10-02 | 2021-09-30 | Processo para preparar um composto de fórmula i, compostos, processos para preparar o composto 1, forma cristalina, composição farmacêutica, processo de preparação da forma cristalina do composto i e método para tratar uma condição neurodegenerativa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230312473A1 (pt) |
| EP (1) | EP4222154A1 (pt) |
| JP (1) | JP2023544037A (pt) |
| KR (1) | KR20230079123A (pt) |
| CN (1) | CN116744933A (pt) |
| AU (1) | AU2021353532A1 (pt) |
| BR (1) | BR112023005853A2 (pt) |
| CA (1) | CA3200566A1 (pt) |
| CL (1) | CL2023000945A1 (pt) |
| CR (1) | CR20230183A (pt) |
| IL (1) | IL301266A (pt) |
| MX (1) | MX2023003759A (pt) |
| PE (1) | PE20230781A1 (pt) |
| WO (1) | WO2022072721A1 (pt) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| US20120328609A1 (en) | 2009-10-22 | 2012-12-27 | Genentech, Inc. | Modulation of Axon Degeneration |
| MY182082A (en) | 2013-05-01 | 2021-01-18 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
-
2021
- 2021-09-30 MX MX2023003759A patent/MX2023003759A/es unknown
- 2021-09-30 KR KR1020237013971A patent/KR20230079123A/ko unknown
- 2021-09-30 CA CA3200566A patent/CA3200566A1/en active Pending
- 2021-09-30 JP JP2023520162A patent/JP2023544037A/ja active Pending
- 2021-09-30 BR BR112023005853A patent/BR112023005853A2/pt unknown
- 2021-09-30 CR CR20230183A patent/CR20230183A/es unknown
- 2021-09-30 EP EP21806494.7A patent/EP4222154A1/en active Pending
- 2021-09-30 IL IL301266A patent/IL301266A/en unknown
- 2021-09-30 AU AU2021353532A patent/AU2021353532A1/en active Pending
- 2021-09-30 WO PCT/US2021/053005 patent/WO2022072721A1/en active Application Filing
- 2021-09-30 PE PE2023001333A patent/PE20230781A1/es unknown
- 2021-09-30 CN CN202180067829.1A patent/CN116744933A/zh active Pending
-
2023
- 2023-03-30 CL CL2023000945A patent/CL2023000945A1/es unknown
- 2023-03-31 US US18/194,423 patent/US20230312473A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000945A1 (es) | 2023-09-29 |
| US20230312473A1 (en) | 2023-10-05 |
| CA3200566A1 (en) | 2022-04-07 |
| AU2021353532A8 (en) | 2023-05-04 |
| MX2023003759A (es) | 2023-04-24 |
| IL301266A (en) | 2023-05-01 |
| JP2023544037A (ja) | 2023-10-19 |
| CR20230183A (es) | 2023-06-14 |
| AU2021353532A1 (en) | 2023-04-13 |
| WO2022072721A1 (en) | 2022-04-07 |
| EP4222154A1 (en) | 2023-08-09 |
| PE20230781A1 (es) | 2023-05-09 |
| CN116744933A (zh) | 2023-09-12 |
| KR20230079123A (ko) | 2023-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107530322B (zh) | 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 | |
| CN104496952B (zh) | 一种达格列净的合成方法 | |
| Palmisano et al. | Influence of the substituent on selective photocatalytic oxidation of aromatic compounds in aqueous TiO 2 suspensions | |
| EP1940528A4 (en) | METHOD USING RARE EARTH TO REMOVE OXYANIONS FROM AQUEOUS FLOWS | |
| WO2009063487A3 (en) | An improved process for manufacture of epoxides, particularly epichlorohydrin | |
| WO2006091731A3 (en) | Processes for the preparation of linezolid intermediate | |
| CN109081807B (zh) | 一种制备三取代4-氨基咔唑类和二取代1-氨基二苯并[b,d]噻吩类化合物的方法 | |
| FR2815962B1 (fr) | Procede de preparation des n-carboxyanhydrides | |
| Atarod et al. | Ultrasound irradiation and green synthesized CuO-NiO-ZnO mixed metal oxide: An efficient sono/nano-catalytic system toward a regioselective synthesis of 1-aryl-5-amino-1 H-tetrazoles | |
| BR112023005853A2 (pt) | Processo para preparar um composto de fórmula i, compostos, processos para preparar o composto 1, forma cristalina, composição farmacêutica, processo de preparação da forma cristalina do composto i e método para tratar uma condição neurodegenerativa | |
| Saravanan et al. | Tetraethylammonium tetraselenotungstate: a new and efficient selenium transfer reagent for the chemoselective synthesis of functionalised diselenides | |
| CN101265271A (zh) | 培南类药物中间体4aa的合成方法 | |
| CN111004198B (zh) | 一种苯并吡喃衍生物的合成方法 | |
| EP2081920A4 (en) | PROCESS FOR PREPARING CRYSTALLINE 3-O-ALKYLASCORBIC ACID | |
| CN101121695A (zh) | 含氮鎓盐化合物的制备方法 | |
| WO2007023496A3 (en) | Process of preparing bromopicrin | |
| CN1041924C (zh) | 硫醇、硫醇盐、二硫代氨基甲酸或其盐的氧化方法 | |
| CN101671300B (zh) | 一种2-氰基-3,6-二氯吡啶的制备方法 | |
| Wang et al. | Highly enantioselective reaction of lithiated N-Boc-thiazolidine: a new chiral formyl anion equivalent | |
| CN104788415B (zh) | 一种不对称合成4‑硝基甲基‑3‑苄基‑3,4‑二氢香豆素衍生物的方法 | |
| EP1595862A4 (en) | PROCESS FOR PRODUCING IODIC COMPOUNDS AND PROCESS FOR PRODUCING HIGH-PURITY 5-IODO-2-METHILBENZOIC ACID | |
| CN102391175A (zh) | 2,2'-联吡啶-4,4'-二甲醛的绿色合成方法 | |
| PT1230211E (pt) | Processo para a preparacao de cetiminas | |
| EP1285917A4 (en) | PROCESS FOR THE PREPARATION OF CARBOSTYRIL DERIVATIVES | |
| EP2468702B1 (en) | Method for producing aryl, heteroaryl, or alkenyl-substituted unsaturated hydrocarbon |